TECHNICAL DATA SHEET







PRODUCT INFORMATION

DuPont™ Tyvek® 500 Jacket with hood model PP33. Stitched internal seams. Zip. White.

ATTRIBUTES	
Full Part Number	TYPP33SWH00
Fabric/Materials	Tyvek®
Design	Jacket with hood
Seam	Stitched (internal)
Color	White
Sizes	MD, LG, XL, 2X
Quantity/Box	50 per box, bulk packed.

FEATURES

- Certified according to Regulation (EU) 2016/425.
- Partial body chemical protective clothing, Category III, Type PB [6-B].
- EN 14126 (barrier to infective agents)
- Antistatic treatment (EN 1149-1) on both sides; see footnotes

SIZETABLE

PRODUCT SIZE	ARTICLE NUMBER	ADDITIONAL INFO	
MD	D13496063		
LG	D13496057		
XL	D13396450		
2X	D13496041		

PHYSICAL PROPERTIES

PROPERTY	TEST METHOD	TYPICAL RESULT	EN
Abrasion Resistance ⁷	EN 530 Method 2	>100 cycles	2/6 ¹
Basis Weight	DIN EN ISO 536	41.5 g/m ²	N/A
Colour	N/A.	White	N/A
Exposure to high Temperature	N/A.	Melting point ~135 °C	N/A
Flex Cracking Resistance ⁷	EN ISO 7854 Method B	>100000 cycles	6/6 ¹
Puncture Resistance	EN 863	>10 N	2/6 1
Resistance to water penetration	AATCC 127	>10 kPa	N/A
Surface Resistance at RH 25%, inside 7	EN 1149-1	< 2,5 • 10 ⁹ Ohm	N/A
Surface Resistance at RH 25%, outside ⁷	EN 1149-1	< 2,5 • 10 ⁹ Ohm	N/A
Tensile Strength (MD)	DIN EN ISO 13934-1	>60 N	2/6 ¹
Tensile Strength (XD)	DIN EN ISO 13934-1	>60 N	2/6 ¹
Trapezoidal Tear Resistance (MD)	EN ISO 9073-4	>10 N	1/6 1
Trapezoidal Tear Resistance (XD)	EN ISO 9073-4	>10 N	1/6 ¹





1 According to EN 14325 | 2 According to EN 14126 | 3 According to EN 1073-2 | 4 According to EN 14116 | 12 According to EN 11612 | 5 Front Tyvek ® / Back |

6 Based on test according to ASTM D-572 | 7 See Instructions for Use for further information, limitations and warnings | > Larger than | < Smaller than |

<= Smaller than or equal to | N/A Not Applicable | STD DEV Standard Deviation |

GARMENT PERFORMANCE

PROPERTY	TEST METHOD	TYPICAL RESULT	EN
Seam Strength	EN ISO 13935-2	>50 N	2/6 ¹
Shelf Life ⁷	N/A.	10 years ⁶	N/A
Type PB 6: Partial Body Protection	EN 13034	Pass	N/A

1 According to EN 14325 | 3 According to EN 1073-2 | 12 According to EN 11612 | 13 According to EN 11611 | 5 Front Tyvek ® / Back |

6 Based on test according to ASTM D-572 | 7 See Instructions for Use for further information, limitations and warnings |

11 Based on the average of 10 suits, 3 activities, 3 probes | > Larger than | < Smaller than | <= Smaller than or equal to | N/A Not Applicable |

COMFORT

PROPERTY	TEST METHOD	TYPICAL RESULT	EN
Air Permeability (Gurley method)	TAPPI T460	< 45 s	N/A

2 According to EN 14126 | 5 Front Tyvek @ / Back | > Larger than | < Smaller than | <= Smaller than or equal to | N/A Not Applicable |

PENETRATION AND REPELLENCY

PROPERTY	TEST METHOD	TYPICAL RESULT	EN
Repellency to Liquids, Sodium Hydroxide (10%)	EN ISO 6530	>95 %	3/3 ¹
Repellency to Liquids, Sulphuric Acid (30%)	EN ISO 6530	>95 %	3/3 ¹
Resistance to Penetration by Liquids, Sodium Hydroxide (10%)	EN ISO 6530	<1 %	3/3 ¹
Resistance to Penetration by Liquids, Sulphuric Acid (30%)	EN ISO 6530	<1 %	3/3 ¹

1 According to EN 14325 \mid > Larger than \mid < Smaller than \mid <= Smaller than or equal to \mid

BIOLOGICAL BARRIER

PROPERTY	TEST METHOD	TYPICAL RESULT	EN
Resistance to Penetration by Biologically Contaminated Aerosols	ISO/DIS 22611	1 < log ratio < 3	1/3 ²
Resistance to Penetration by Blood and Body Fluids using Synthetic Blood	ISO 16603	3,5 kPa	3/6 ²

^{*} Based on lowest single value |





PROPERTY	TEST METHOD	TYPICAL RESULT	EN
Resistance to Penetration by Blood-borne Pathogens using Bacteriophage Phi-X174	ISO 16604 Procedure C	1,75 kPa	2/6 ²
Resistance to Penetration by Contaminated Liquids	EN ISO 22610	<u><</u> 15 min	1/6 ²
Resistance to Penetration by Contaminated Solid Particles	ISO 22612	2 < log cfu < 3	1/3 ²

¹ According to EN 14325 $\,$ | > Larger than $\,$ | < Smaller than $\,$ | <= Smaller than or equal to $\,$ |

PERMEATION DATA DUPONT™ TYVEK® 500 ACCESSORY

HAZARD / CHEMICAL NAME PHYSICAL STATE CAS BT ACT BT,	0.001 0.005 0.014 05 0.005 0.005 0.001 1 0.01 002 0.0002
Ammonium hydroxide Liquid 1336-21-6 imm imm imm 16.7 Carboplatin (10 mg/ml) Liquid 154-93-8 imm imm imm 20.3 Carmustine (3.3 mg/ml, 10 Liquid 154-93-8 imm imm imm 20.3 Caustic ammonia (16%) Liquid 1336-21-6 imm imm imm 20.3 Caustic ammonia (28% - 1 Liquid 1336-21-6 imm imm imm 16.7 Caustic soda (10%) Liquid 1310-73-2 2240 2480 2480 6 <0.00 Caustic soda (10%) Liquid 1310-73-2 imm 30 2240 5 <0.00 Caustic soda (40%) Liquid 1310-73-2 imm 30 2240 5 <0.00 Caustic soda (50%) Liquid 1310-73-2 imm 30 2240 5 <0.00 Caustic soda (50%) Liquid 1310-73-2 imm 2480 2480 2480 6 <0.01 Cisplatin (1 mg/ml) Liquid 15663-27-1 2240 2240 2240 5 <0.00 Cyclo phosphamide (20 Liquid 50-18-0 2240 2240 5 <0.00 Cyclo phosphamide (20 Liquid 107-21-1 imm imm imm imm 6.6 Ethylene glycol Liquid 107-21-1 imm imm imm imm 6.6 Ethylene glycol Liquid 33419-42-0 2240 2240 5 <0.00 Caustic soda (70%) Liquid 51-21-8 imm imm imm imm mm Canciclovir (3 mg/ml) Liquid 82410-32-0 2240 2240 5 <0.00 Caustic soda (10%) Liquid 107-21-1 imm imm imm imm mm Canciclovir (3 mg/ml) Liquid 64-18-6 imm imm imm imm Canciclovir (3 mg/ml) Liquid 56-81-5 2240 2480 2480 6 0.03 Caustic soda (10%) Liquid 56-81-5 2240 2480 2480 6 0.03 Caustic soda (10%) Liquid 56-81-5 2240 2480 2480 6 0.03 Caustic soda (10%) Liquid 56-81-5 2240 2480 2480 6 0.03 Caustic soda (10%) Liquid 56-81-5 2240 2480 2480 6 0.03 Caustic soda (10%) Liquid 56-81-5 2240 2480 2480 6 0.03 Caustic soda (10%) Liquid 56-81-5 2240 2480 2480 6 0.03 Caustic soda (10%) Liquid 56-81-5 2240 2480 2480 6 0.03 Caustic soda (10%) Liquid 56-81-5 2240 2480 2480 6 0.03 Caustic soda (10%) Liquid 56-81-5	0.014 01 0.001 0.001 0.005 0.014 05 0.005 05 0.005 0.01 1 0.01
Liquid 1336-21-6 Imm I	01 0.001 0.001 0.005 0.014 05 0.005 0.005 0.001 1 0.01
tarmustine (3.3 mg/ml, 10 & Liquid 154-93-8 imm imm >240 5 <0.3 (austic ammonia (16%)	0.001 0.005 0.014 05 0.005 0.005 0.001 1 0.01 002 0.0002
Liquid 134-93-8 Imm Imm >240 5 <0.3 caustic ammonia (16%) Liquid 1336-21-6 Imm Imm Imm 20.3 caustic ammonia (28% - 0%) Liquid 1310-73-2 >240 >480 >480 6 <0.00 caustic soda (10%) Liquid 1310-73-2 Imm >30 >240 5 <0.00 caustic soda (40%) Liquid 1310-73-2 Imm >30 >240 5 <0.00 caustic soda (50%) Liquid 1310-73-2 Imm >30 >240 5 <0.00 caustic soda (50%) Liquid 1310-73-2 Imm >30 >240 5 <0.00 caustic soda (50%) Liquid 1310-73-2 Imm >30 >240 5 <0.00 caustic soda (50%) Liquid 1310-73-2 Imm >30 >240 5 <0.00 caustic soda (50%) Liquid 1310-73-2 Imm >30 >240 5 <0.00 caustic soda (50%) Liquid 15663-27-1 >240 >240 >240 5 <0.00 caustic soda (50%) Liquid 50-18-0 >240 >240 >240 5 <0.00 caustic soda (50%) Liquid 50-18-0 >240 >240 >240 5 <0.00 caustic soda (50%) Liquid 50-18-0 >240 >240 >240 5 <0.00 caustic soda (50%) Liquid 107-21-1 Imm Imm Imm Imm 6.6 caustic soda (50%) Liquid 107-21-1 Imm Imm Imm 1mm 6.6 caustic soda (50%) Liquid 107-21-1 Imm Imm Imm 1mm 6.6 caustic soda (50%) Liquid 51-21-8 Imm Imm Imm Imm 1mm 1mm 1mm 1mm 1mm 1mm	0.005 0.014 05 0.005 0.005 0.001 1 0.01 002 0.0002
Liquid 1336-21-6 imm imm imm 16.7 Liquid 1310-73-2 >240 >480 >480 6 <0.00 Liquid 1310-73-2 imm >30 >240 5 <0.00 Liquid 1310-73-2 >480 >480 >480 6 <0.01 Liquid 15663-27-1 >240 >240 >240 5 <0.00 Liquid 50-18-0 >240 >240 >240 5 <0.00 Liquid 77-78-1 imm imm imm imm >160 Doxorubicin HCl (2 mg/ml) Liquid 25136-40-9 >240 >240 >240 5 <0.00 Liquid 107-21-1 imm imm imm imm 6.6 Liquid 107-21-1 imm imm imm imm 6.6 Liquid 107-21-1 imm imm imm imm imm mm imm imm 6.6 Liquid 107-21-1 imm imm imm imm imm imm imm imm imm im	0.014 05 0.005 05 0.005 0.01 1 0.01 002 0.0002
Liquid 1310-73-2 >240 >480 >480 6 <0.00 (austic soda (10%)	05
Caustic soda (40%)	05 0.005 0.01 1 0.01 002 0.0002
Equatic soda (50%) Liquid 1310-73-2 imm >30 >240 5 0.85 (austic soda (>95%, solid) Solid 1310-73-2 >480 >480 >480 6 <0.01 (austic soda (>95%, solid) Liquid 15663-27-1 >240 >240 >240 5 <0.00 (austic soda (>95%, solid) Liquid 15663-27-1 >240 >240 >240 5 <0.00 (austic soda (>95%, solid) Liquid 15663-27-1 >240 >240 >240 5 <0.00 (austic soda (>95%, solid) Liquid 50-18-0 >240 >240 >240 5 <0.00 (austic soda (>95%, solid) Liquid 150-18-0 >240 >240 >240 5 <0.00 (austic soda (>95%, solid) Liquid 150-18-0 >240 >240 >240 5 <0.00 (austic soda (>95%, solid) Liquid 15136-40-9 >240 >240 >240 5 <0.00 (austic soda (>95%, solid) Liquid 107-21-1 imm imm imm imm 6.6 (austic solid) Liquid 107-21-1 imm imm imm imm 6.6 (austic solid) Liquid 107-21-1 imm imm imm imm 6.6 (austic solid) Liquid 107-21-1 imm imm imm imm 100 (austic solid) Liquid 107-21-1 imm 100 (austic solid) Liquid 107-21-1 imm imm imm 100 (austic solid) Liquid 107-21-1 imm imm imm imm 100 (austic solid) Liquid 107-21-1 imm imm imm imm 100 (austic solid) Liquid 107-21-1 imm imm imm imm 100 (austic solid) Liquid 107-21-1 imm imm imm imm 100 (austic solid) Liquid 107-21-1 imm imm imm imm 100 (austic solid) Liquid 107-21-1 imm imm imm imm 100 (austic solid) Liquid 107-21-1 imm imm imm imm 100 (austic solid) Liquid 107-21-1 imm imm imm imm 100 (austic solid) Liquid 107-21-1 imm imm imm imm 100 (austic solid) Liquid 107-21-1 imm imm imm imm 100 (austic solid) Liquid 107-21-1 imm imm imm imm 100 (austic solid) Liquid 107-21-1 imm imm imm imm 100 (austic solid) Liquid 107-21-1 imm imm imm imm 100 (austic solid) Liquid 107-21-1 imm imm imm imm 100 (austic solid) Liquid 107-21-1 imm imm imm imm 100 (austic solid) Liquid 107-21-1 imm imm imm 100 (austic solid) Liquid 107-21-1 imm imm imm 100 (austic solid) Liquid 107-21-1 imm imm 100 (austic solid) L	0.01 1 0.01 002 0.0002
Caustic soda (>95%, solid) Solid So	1 0.01 002 0.0002
Cisplatin (1 mg/ml) Liquid 15663-27-1 >240 >240 5 <0.00	002 0.0002
Cyclo phosphamide (20 mg/ml) Liquid 50-18-0 >240 >240 5 <0.00 mg/ml)	
ng/ml) Liquid 50-18-0 >240 >240 >240 5 <0.00 Dimethyl sulfate Liquid 77-78-1 imm imm imm >160 Doxorubicin HCl (2 mg/ml) Liquid 25136-40-9 >240 >240 >240 5 <0.00	02 0.002
Doxorubicin HCl (2 mg/ml) Liquid 25136-40-9 >240 >240 >240 5 <0.00 Ethane 1,2-diol Liquid 107-21-1 imm imm imm 6.6 Ethylene glycol Liquid 107-21-1 imm imm imm 6.6 Etoposide (Toposar®, Eeva) (20 mg/ml, 33.2 % (v. V) Liquid 33419-42-0 >240 >240 >240 5 <0.01	
thane 1,2-diol Liquid 107-21-1 imm imm imm 6.6 thylene glycol Liquid 107-21-1 imm imm imm 6.6 toposide (Toposar®, eva) (20 mg/ml, 33.2 % (v Liquid 33419-42-0 >240 >240 >240 5 <0.01 tupocuracil, 5- (50 mg/ml) Liquid 51-21-8 imm imm imm nm ormic acid (30%) Liquid 64-18-6 imm imm imm nm imm nm imm nm imm imm sianciclovir (3 mg/ml) Liquid 82410-32-0 >240 >240 >240 5 <0.00 tupocuracil, 5- (50 mg/ml) Liquid 82410-32-0 >240 >240 >240 5 <0.00 tupocuracil, 5- (50 mg/ml) Liquid 82410-32-0 >240 >240 5 <0.00 tupocuracil, 5- (50 mg/ml) Liquid 95058-81-4 imm >60 >240 5 <0.00 tupocuracil, 5- (50 mg/ml) Liquid 95058-81-5 >240 >480 >480 6 0.03 tupocuracil, 5- (50 mg/ml) Liquid 56-81-5 >240 >480 >480 6 0.03 tupocuracil, 5- (50 mg/ml) Liquid 56-81-5 >240 >480 >480 6 0.03 tupocuracil, 5- (50 mg/ml) Liquid 56-81-5 >240 >480 >480 6 0.03 tupocuracil, 5- (50 mg/ml) Liquid 107-21-1 imm imm imm imm 6.6	0.02
thylene glycol Liquid 107-21-1 imm imm imm 6.6 toposide (Toposar®, eva) (20 mg/ml, 33.2 % (v Liquid 33419-42-0 >240 >240 >240 5 <0.01 v) Ethanol) luorouracil, 5- (50 mg/ml) Liquid 51-21-8 imm imm >30 2 na ormic acid (30%) Liquid 64-18-6 imm imm imm nm ianciclovir (3 mg/ml) Liquid 82410-32-0 >240 >240 >240 5 <0.00 immic acid (38 mg/ml) Liquid 95058-81-4 imm >60 >240 5 <0.00 immic acid (38 mg/ml) Liquid 56-81-5 >240 >480 >480 6 0.03 ilycerol Liquid 56-81-5 >240 >480 >480 6 0.03 ilycol alcohol Liquid 107-21-1 imm imm imm imm 6.6	03 0.003
(toposide (Toposar®, eva) (20 mg/ml, 33.2 % (v Eva) (20 mg/ml, 33.2 % (v Eva) (20 mg/ml, 33.2 % (v Ethanol) Liquid 33419-42-0 >240 >240 5 <0.01	0.002
Teva) (20 mg/ml, 33.2 % (v Liquid 33419-42-0 >240 >240 >240 5 <0.01 (v) Ethanol) Fluorouracil, 5- (50 mg/ml)	0.002
Formic acid (30%) Liquid 64-18-6 imm imm imm nm Sanciclovir (3 mg/ml) Liquid 82410-32-0 >240 >240 >240 5 <0.00 Semcitabine (38 mg/ml) Liquid 95058-81-4 imm >60 >240 5 <0.4 Slycerine Liquid 56-81-5 >240 >480 >480 6 0.03 Slycerol Liquid 56-81-5 >240 >480 >480 6 0.03 Slycol alcohol Liquid 107-21-1 imm imm imm 6.6	1 <0.01
Ganciclovir (3 mg/ml) Liquid 82410-32-0 >240 >240 5 <0.00	0.001
Gemcitabine (38 mg/ml) Liquid 95058-81-4 imm >60 >240 5 <0.4	0.001
Silycerine Liquid 56-81-5 >240 >480 >480 6 0.03 Silycerol Liquid 56-81-5 >240 >480 >480 6 0.03 Silycol alcohol Liquid 107-21-1 imm imm imm 6.6	05 0.005
Slycerol Liquid 56-81-5 >240 >480 >480 6 0.03 Slycol alcohol Liquid 107-21-1 imm imm imm 6.6	0.005
Slycol alcohol Liquid 107-21-1 imm imm imm 6.6	0.01
	0.01
lydrochloric acid (16%) Liquid 7647-01-0 imm imm na	0.002
	0.05
Hydrochloric acid (32%) Liquid 7647-01-0 imm imm ma	0.05
Hydrogen peroxide (10%) Liquid 7722-84-1 >10 >10 >480 6 <0.01	1 0.01
lydrogen peroxide (30%) Liquid 7722-84-1 imm imm imm >0.11	0.04
fosfamide (50 mg/ml) Liquid 3778-73-2 imm imm >240 5 <0.5	0.003 >480 6
rinotecan (20 mg/ml) Liquid 100286-90-6 imm >240 >240 5 <0.1	0.0028
Methotrexate (25 mg/ml, Liquid 59-05-2 >240 >240 >240 5 <0.00	
Mitomycin (0.5 mg/ml) Liquid 50-07-7 >240 >240 >240 5 <0.00	01 0.001
licotine (9 mg/ml) Liquid 54-11-5 >480 >480 >480 6 <0.08	
Nitric acid (10%) Liquid 7697-37-2 >60 >120 >480 6 na	0.0009





HAZARD / CHEMICAL NAME	PHYSICAL STATE	CAS	вт аст	BT 0.1	BT 1.0	EN	SSPR	MDPR	CUM 480	TIME 150	ISO
Nitric acid (30%)	Liquid	7697-37-2	imm	imm	imm		4.6	0.001			
Oxaliplatin (5 mg/ml)	Liquid	63121-00-6	imm	imm	imm		na	0.006			
Paclitaxel (Hospira) (6 mg /ml, 49.7 % (v/v) Ethanol)	Liquid	33069-62-4	>240	>240	>240	5	<0.01	<0.01			
Phosphoric acid (50%)	Liquid	7664-38-2	>480	>480	>480	6	<0.05	0.05			
Potassium chromate (sat)	Liquid	7789-00-6	>480	>480	>480	6	<0.005	0.005			
Potassium hydroxide (40%)	Liquid	1310-58-3	imm	imm	>30	2	0.7	0.001			
Propane -1,2,3-triol	Liquid	56-81-5	>240	>480	>480	6	0.03	0.01			
Sodium acetate (sat)	Liquid	127-09-3	imm	>480	>480	6	<0.1	0.05		>480	6
Sodium chloride (9 g/l)	Liquid	7647-14-5	>240	>240	>240	5	<0.02	0.02			
Sodium hydroxide (10%)	Liquid	1310-73-2	>240	>480	>480	6	<0.005	0.005			
Sodium hydroxide (40%)	Liquid	1310-73-2	imm	>30	>240	5	<0.005	0.005			
Sodium hydroxide (50%)	Liquid	1310-73-2	imm	>30	>240	5	0.85	0.01			
Sodium hydroxide (>95%, solid)	Solid	1310-73-2	>480	>480	>480	6	<0.01	0.01			
Sodium hypochlorite (10- 15 % active chlorine)	Liquid	7681-52-9	>240	>240	>480	6	<0.6	0.05			
Sodium hypochlorite (5.25-6%)	Liquid	7681-52-9	>480	>480	>480	6	<0.025	0.025			
Sulfuric acid (18%)	Liquid	7664-93-9	>240	>240	>480	6	<0.05	0.05			
Sulfuric acid (30%)	Liquid	7664-93-9	>10	>240	>240	5	<0.05	0.05			
Sulfuric acid (50%)	Liquid	7664-93-9	imm	>30	>60	3	38	0.01			
Sulfuric acid dimethyl ester	Liquid	77-78-1	imm	imm	imm		>160	0.02			
Thiotepa (10 mg/ml)	Liquid	52-24-4	imm	imm	imm		na	0.001			
Vincristine sulfate (1 mg /ml)	Liquid	2068-78-2	>240	>240	>240	5	<0.001	0.001			
Vinorelbine (0.1 mg/ml)	Liquid	71486-22-1	>240	>240	>240	5	<0.0209	0.00209			

BTAct (Actual) Breakthrough time at MDPR [mins] | BT0.1 Normalized breakthrough time at $0.1 \, \mu g/cm^2/min$ [mins] |

BT1.0 Normalized breakthrough time at 1.0 µg/cm²/min [mins] | EN Classification according to EN 14325 | SSPR Steady state permeation rate [µg/cm²/min] |

MDPR Minimum detectable permeation rate [µg/cm²/min] | CUM480 Cumulative permeation mass after 480 mins [µg/cm²] |

Time150 Time to reach cumulative permeation mass of 150 μg/cm² [mins] | ISO Classification according to ISO 16602 |

CAS Chemical abstracts service registry number | min Minute | > Larger than | < Smaller than | imm Immediate (< 10 min) | nm Not tested |

sat Saturated solution | N/A Not Applicable | na Not attained | GPR grade General purpose reagent grade | * Based on lowest single value |

8 Actual breakthrough time; normalized breakthrough time is not available | DOT5 Degradation after 5 min | DOT30 Degradation after 30 min |

DOT60 Degradation after 60 min | DOT240 Degradation after 240 min | BT1383 Normalized breakthrough time at 0.1 µg/cm²/min [mins] acc. ASTM F1383 |

Important Note

The permeation data published have been generated for DuPont by independent accredited testing laboratories according to the test method applicable at that time (EN ISO 6529 (method A and B), ASTM F739, ASTM F1383, ASTM D6978, EN369, EN 374-3) The data is typically the average of three fabrics samples tested. All chemicals have been tested at an assay of greater than 95 (w/w) % unless otherwise stated. The tests were performed between 20 °C and 27 °C and at environmental pressure unless otherwise stated. A different temperature may have significant influence on the breakthrough time. Permeation typically increases with temperature. Cumulative permeation data have been measured or have been calculated based on minimum detectable permeation rate. Cytostatic drugs testing has been performed at a test temperature of 27°C according to ASTM D6978 or ISO 6529 with the additional requirement of reporting a normalized breakthrough time at 0.01 µg/cm²/min. Chemical warfare agents (Lewisite, Sarin, Soman, Mustard, Tabun and VX Nerve Agent) have been tested according to MIL-STD-282 at 22°C or according to FINABEL 0.7 at 37°C. Permeation data for Tyvek® is applicable to white Tyvek® 500 and Tyvek® 600 only and is not applicable for other Tyvek® styles or colours. Permeation data are usually measured for single chemicals. The permeation characteristics of mixtures can often deviate considerably from the behaviour of the individual chemicals. The permeation data for gloves published have been generated according to ASTM F1383. The degradation data for gloves published have been generated based on a gravimetric method. This degradation testing exposes one side of the glove material to the test chemical for four hours. The percent weight change after exposure is measured at four time intervals: 5, 30, 60 and 240 minutes.

Degradation Ratings:

- E: EXCELLENT (0-10% Weight Change)
- G: GOOD (11-20% Weight Change)





- F: FAIR (21-30% Weight Change)
- P: POOR (31-50% Weight Change)
- NR: NOT RECOMMENDED (Above 50% Weight Change)
- NT: NOT TESTED

Degradation is the physical change in a material after chemical exposure. Typical observable effects may be swelling, wrinkling, deterioration, or delamination. Strength loss may also occur.

Please use the permeation data provided as a part of the risk assessment to assist with the selection of a protective fabric, garment, glove or accessory suitable for your application. Breakthrough time is not the same as safe wear time. Breakthrough times are indicative of the barrier performance, but results can vary between the test methods and laboratories. Breakthrough time alone is insufficient to determine how long a garment may be worn once the garment has been contaminated. Safe user wear time may be longer orshorter than the breakthrough time depending on the permeation behaviour of the substance, the toxicity of the substance, working conditions and the exposure conditions (e.g. temperature, pressure, concentration, physical state).

Latest Update Permeation Data: 10/24/2022

The information provided herein corresponds to our knowledge on the subject at the date of its publication. This information may be subject to revision as new knowledge and experience becomes available. The data provided fall within the normal range of product properties and relate only to the specific material designated; these data may not be valid for such material used in combination with any other materials or additives or in any process, unless expressly indicated otherwise. The data provided should not be used to establish specification limits or used alone as the basis of design; they are not intended to substitute for any testing you may need to conduct to determine for yourself the suitability of a specific material for your particular purposes. Since DuPont cannot anticipate all variations in actual end-use conditions DuPont makes no warranties and assumes no liability in connection with any use of this information. Nothing in this publication is to be considered as a license to operate under or a recommendation to infringe any patent rights.

WARNING

The information provided herein corresponds to our knowledge on the subject at the date of its publication. This information may be subject to revision as new knowledge and experience becomes available. The data provided fall within the normal range of product properties and relate only to the specific material designated; these data may not be valid for such material used in combination with any other materials or additives or in any process, unless expressly indicated otherwise. The data provided should not be used to establish specification limits or used alone as the basis of design; they are not intended to substitute for any testing you may need to conduct to determine for yourself the suitability of a specific material for your particular purposes. Since DuPont cannot anticipate all variations in actual end-use conditions DuPont makes no warranties and assumes no liability in connection with any use of this information. Nothing in this publication is to be considered as a license to operate under or a recommendation to infringe any patent rights.

This garment and/or fabric are not flame resistant and should not be used around heat, open flame, sparks or in potentially flammable environments.

Working in Ex-Zones: Please take this into account for your risk-assessment that the attached socks may isolate the wearer. There is the possibility that the garment and wearer cannot by grounded via the shoes and other measures for grounding the garment and the wearer are required

DuPont™ SafeSPEC™ - We're here to help

Our powerful web-based tool can assist you with finding the appropriate DuPont garments for chemical and controlled environment hazards.





CREATED ON: MARCH 14, 2025

© 2024 DuPont. All rights reserved. DuPont $^{\text{TM}}$, the DuPont Oval Logo, and all trademarks and service marks denoted with $^{\text{TM}}$, so $^{\text{O}}$ are owned by affiliates of DuPont de Nemours, Inc. unless otherwise noted.